Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Safety Study of Interferon Beta-1a for Acute Stroke
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Daclizumab discontinue letter for the US market
Alemtuzumab and multiple sclerosis: therapeutic application.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Withdrawal of the marketing authorization in the European Union

Pages